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Summary
Ombitasvir/paritaprevir/ritonavir	±	dasabuvir	±	ribavirin	 (OBV/PTV/r	±	DSV	±	RBV)	
regimens	show	high	efficacy	and	good	tolerability	in	clinical	trials	for	chronic	hepati-
tis	C	virus	(HCV)	genotypes	(GT)	1	or	4.	To	evaluate	whether	these	results	translate	
to	clinical	practice,	data	were	pooled	from	observational	studies	across	13	countries.	
Treatment-	naïve	or	-	experienced	patients,	with	or	without	cirrhosis,	received	OBV/
PTV/r	±	DSV	±	RBV	according	to	approved	local	labels	and	clinical	practice.	Sustained	
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1 | INTRODUC TION
Since	 their	 introduction	 in	 2013,	 second-	generation	 direct-	
acting	 antiviral	 (DAA)	 drugs	 have	 improved	 the	 efficacy,	 safety	
and	tolerability	of	treatment	for	chronic	hepatitis	C	virus	 (HCV)	
infection.	 All-	oral,	 interferon-	free	 DAA	 combination	 regimens	
comprising	 ombitasvir/paritaprevir/ritonavir	+	dasabuvir	 (OBV/
PTV/r+DSV)	±	ribavirin	 (RBV)	 and	 OBV/PTV/r	+	RBV	 were	 ap-
proved	for	use	in	the	United	States	and	Europe	in	2014-	20151–4 
and	are	recommended	for	the	treatment	of	HCV	genotypes	(GT)	
1	 and	 4,	 respectively.5,6	 In	 GT1a-	infected	 patients	 without	 cir-
rhosis,	OBV/PTV/r	+	DSV	+	RBV	is	administered	for	12	weeks,	or	
for	 24	weeks	 in	 patients	 with	 compensated	 cirrhosis.	 In	 GT1b-	
infected	patients	without	cirrhosis	or	with	compensated	cirrho-
sis,	OBV/PTV/r	+	DSV	 is	administered	 for	12	weeks	 (or	8	weeks	
with	 mild	 fibrosis	 [F0-	F2]).2,3	 In	 GT4-	infected	 patients,	 OBV/
PTV/r	+	RBV	is	administered	for	12	weeks	regardless	of	cirrhosis	
status.1–4	 These	multitargeted	DAA	 regimens	 have	 shown	 good	
tolerability	and	high	rates	of	sustained	virologic	response	at	post-	
treatment	Week	12	(SVR12)	in	a	broad	range	of	adult	patients	in	
pivotal	clinical	trials.7–12	As	of	April	2017,	OBV/PTV/r	+	DSV	regi-
mens	are	approved	in	more	than	80	countries,	and	OBV/PTV/r	in	
more than 50 countries.
Notwithstanding	 the	 success	 of	 DAA	 regimens,	 barriers	 to	
HCV	 treatment	 initiation	 remain,	with	 the	presence	of	 comorbidi-
ties	and	the	potential	risk	for	drug-	drug	interactions	(DDIs)	cited	as	
common	 impediments.5	 Patients	with	 chronic	HCV	 infection	have	
a	high	burden	of	comorbid	medical	and	psychiatric	conditions,13–15 
which	 are	 often	 managed	 with	 multiple	 comedications.16 Among 
patients	 treated	with	 currently	 available	DAA	 drugs	who	 are	 tak-
ing	comedications,	at	 least	30%	are	potentially	at	risk	for	clinically	
significant	 DDIs,17	 although	 these	 risks	 vary	 between	 individual	
drugs.	Clinically	 significant	DDIs	with	 commonly	 prescribed	drugs	
and	over-	the-	counter	medications	have	been	established	for	OBV/
PTV/r	±	DSV	based	on	drug	interaction	studies.
In	clinical	practice,	the	effectiveness	of	DAA	therapies	may	be	
lower	than	in	clinical	trials	because	patient	populations	tend	to	be	
more	diverse	(eg	patients	may	be	older,	have	more	advanced	disease	
or	 have	 additional	 comorbidities)	 and	 less	 adherent	 to	 treatment	
regimens.18	 Furthermore,	 clinical	 trials	 are	 designed	 to	 establish	
efficacy outcomes of investigative drugs and are conducted in con-
trolled settings, with strict eligibility criteria that are intended to 
enroll	well-	defined	trial	populations	with	 limited	comorbidities	or	
comedications to mitigate any unwarranted influence on treatment 
safety	and	efficacy	outcomes.	Therefore,	the	results	from	clinical	
virologic	response	at	post-	treatment	Week	12	(SVR12),	adverse	events	(AEs)	and	co-
medication	 management	 were	 assessed	 for	 patients	 initiating	 treatment	 before	 1	
June	2017.	The	safety	population	 included	3850	patients	who	received	≥1	dose	of	
study	drug.	The	core	population	(N	=	3808)	further	excluded	patients	with	unknown	
GT	or	cirrhosis	status,	or	who	received	off-	label	treatment.	Patients	had	HCV	GT1a	
(n	=	732;	19%),	GT1b	 (n	=	2619;	69%)	or	GT4	 (n	=	457;	12%).	 In	3546	patients	with	
sufficient	 follow-	up	 data	 at	 post-	treatment	 Week	 12,	 the	 SVR12	 rate	 was	 96%	
(n/N	=	3401/3546	[95%	CI	95.2-	96.5]).	In	patients	with	or	without	cirrhosis,	SVR12	
was	comparable	(96%).	In	patients	with	HCV	GT1a,	GT1b	or	GT4,	SVR12	rates	were	
93%,	97%	and	94%.	In	GT1b-	infected	patients	with	planned	treatment	for	8	weeks,	
SVR12	was	96%.	In	patients	with	≥1	comorbidity	(67%),	SVR12	was	95%.	58%	of	pa-
tients	received	≥1	comedication,	and	there	was	minimal	impact	on	SVR12	rates	using	
comedications	for	peptic	ulcers	and	gastro-	esophageal	reflux	disease,	statins,	antip-
sychotics	or	 antiepileptics.	Most	 comedications	were	maintained	during	 treatment	
although	58%	of	patients	changed	their	statin	medication.	AEs	and	serious	AEs	oc-
curred	in	26%	and	3%	of	patients.	Post-	baseline	Grade	3-	4	laboratory	abnormalities	
were	rare	(<3%),	and	discontinuation	rates	were	low	(<4%).	Real-	world	evidence	con-
firms	 the	 effectiveness	 of	 OBV/PTV/r	±	DSV	±	RBV	 in	 patients	 with	 HCV	GT1	 or	
GT4,	 regardless	of	common	comorbidities	or	comedications,	and	 is	consistent	with	
clinical	trial	results.	Adverse	safety	outcomes	may	be	limited	by	underreporting	in	the	
real-	world	setting.
K E Y W O R D S
comorbidity,	direct-acting	antiviral,	drug-drug	interaction,	hepatitis	C	virus,	real-world	
evidence
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trials	may	not	be	comparable	to	those	from	daily	clinical	practice.	
Studies	using	real-	world	data	collected	during	routine	clinical	care	
provide	additional	evidence	of	treatment	safety	and	effectiveness,	
which	complements	the	results	from	clinical	trials.	Understanding	
the	 safety	 and	 effectiveness	 of	DAA	 regimens	 in	 real-	world	 set-
tings	is	important	to	help	guide	patients	and	healthcare	providers	
in	 clinical	 decision-	making	 as	 well	 as	 to	 help	 inform	 regulatory	
decision-	making.19	 At	 present,	 data	 assessing	 the	 real-	world	 ef-
fectiveness	of	OBV/PTV/r	±	DSV	±	RBV	regimens	in	patients	with	
HCV	are	limited.
In	 this	 pooled	 analysis	 of	 post-	marketing	 observational	 stud-
ies,	we	evaluated	the	real-	world	safety	and	effectiveness	of	OBV/
PTV/r	±	DSV	±	RBV	regimens,	as	well	as	comedication	management,	
in	clinical	practice	in	patients	chronically	infected	with	HCV	GT1	or	
GT4.
2  | MATERIAL S AND METHODS
2.1 | Study design
This	was	 an	 analysis	 of	 data	 pooled	 from	AbbVie-	sponsored,	 pro-
spective,	observational	studies	conducted	at	289	sites	 in	13	coun-
tries:	 Austria	 (NCT02582658),	 Belgium	 (NCT02581163),	 Canada	
(NCT02581189),	Colombia	(NCT02851069),	France	(NCT02618928),	
Germany	 (NCT02615145),	 Greece	 (NCT02725866),	 Hungary	
(NCT02636608),	 Ireland	 (NCT02582671),	 Israel	 (NCT02803138),	
Kuwait	 (NCT02798315),	 Poland	 (NCT02640547)	 and	 Romania	
(NCT02807402).	 In	 some	 countries,	 the	 studies	 are	 still	 ongoing.	
All	 eligible	 patients	 were	 followed	 from	 treatment	 initiation	 until	
12	weeks	after	the	end	of	treatment	(EOT)	(or	until	premature	dis-
continuation,	or	in	accordance	with	local	clinical	practice).
Data	were	 recorded	 in	English	by	each	participating	centre	via	
a	centralized	electronic	data	capture	system	using	web-	based	case	
report	forms	(eCRF).	Examinations,	diagnostic	measures,	laboratory	
assessments,	findings	and	observations	routinely	performed	in	pa-
tients	with	chronic	HCV	infection	included	in	this	cohort	were	tran-
scribed by the investigator or designee from the source documents 
into	the	eCRF.
Each	 study	 was	 conducted	 in	 accordance	 with	 local	 laws	 and	
regulations	 and	 received	 the	 required	 approvals	 from	 the	 respon-
sible	 regulatory	 authorities,	 ethics	 committees	 and/or	 competent	
authorities.
2.2 | Study populations and treatments
Analyses	were	performed	 in	 the	following	populations.	The	safety	
population	included	all	male	or	female	patients	who	were	≥18	years	
of	 age,	 chronically	 infected	with	 HCV	GT1	 or	 GT4	 (or	 with	miss-
ing	GT	 information),	and	who	had	received	≥1	dose	of	study	drug.	
Patients	who	were	treatment-	naïve	or	-	experienced	(previous	treat-
ment	 with	 interferon-	 or	 DAA-	based	 regimens)	 were	 included,	 as	
were	patients	with	or	without	 cirrhosis.	Patients	were	excluded	 if	
they	had	a	missing	 treatment	start	date	or	 initiated	planned	treat-
ment	after	1	June	2017,	or	their	treatment	group	was	missing.
The	core	population	further	excluded	from	the	safety	population	
patients	who	 did	 not	 have	 confirmed	 chronic	HCV	 infection	with	
GT1	or	GT4,	patients	with	cirrhosis	and	GT1a	infection	not	receiv-
ing	RBV,	patients	with	GT1	for	whom	OBV/PTV/r	instead	of	OBV/
PTV/r	+	DSV	was	prescribed,	patients	with	GT4	not	receiving	RBV,	
and	 patients	 with	 unknown	 HCV	 GT	 or	 cirrhosis	 status.	 Patients	
with	missing	SVR12	values	were	counted	as	nonresponders	 in	 the	
core	population.
The	 core	 population	 with	 sufficient	 follow-	up	 (CPSFU)	 in-
cluded	patients	 from	 the	core	population	apart	 from	 those	with	a	
documented	virologic	 response	at	 their	 last	on-	treatment	or	post-	
treatment	measurement	but	with	no	HCV	RNA	measurements	more	
than	 70	days	 post-	treatment	 for	 reasons	 not	 related	 to	 safety	 or	
effectiveness,	 or	 patients	with	 no	HCV	RNA	measurements	 post-	
baseline or no treatment end date for reasons not related to safety 
or	effectiveness	(eg	lost	to	follow-	up,	consent	withdrawal).
Patients	 infected	 with	 HCV	 GT1a	 received	 OBV/
PTV/r	+	DSV	±	RBV	 regimens	 for	 planned	 treatment	 durations	 of	
12	or	24	weeks.	Patients	 infected	with	HCV	GT1b	 received	OBV/
PTV/r	+	DSV	±	RBV	 regimens	 for	 planned	 treatment	 durations	 of	 
12	or	24	weeks.	In	some	cases,	GT1-	infected	patients	did	not	receive	
DSV.	The	HCV	GT1-	infected	population	also	included	patients	with	a	
planned	treatment	duration	of	8	weeks	because	treatment-	naïve	pa-
tients	with	minimal	to	moderate	fibrosis	(F0-	F2)	may	have	been	con-
sidered for this shorter treatment duration based on findings from 
the	GARNET	study	and	according	to	local	label	updates.2,20	Patients	
infected	with	HCV	GT4	received	OBV/PTV/r	±	DSV	+	RBV	regimens	
for	planned	treatment	durations	of	12	or	24	weeks.	In	some	cases,	
patients	infected	with	GT4	did	not	receive	RBV.	The	recommended	
dosage	 of	OBV/PTV/r	was	 25	mg/150	mg/100	mg	once	 daily,	 and	
DSV	was	250	mg	twice	daily;	weight-	based	RBV	was	administered	
according	to	local	label.	The	choice	of	treatment	regimen	was	at	the	
discretion	of	 the	healthcare	provider	 and	was	 consistent	with	 the	
recommended	label	or	with	local	clinical	practice.
2.3 | Assessments
SVR12	 was	 defined	 as	 an	 HCV	 RNA	 concentration	<50	IU/mL	 at	
12	weeks	 after	 EOT	 (70-	126	days	 after	 the	 last	 dose).	 HCV	 RNA	
measurements	 were	 considered	<50	IU/mL	 if	 HCV	 RNA	 was	 un-
detectable and the lower limit of detection of the assay was 
≤50	IU/mL;	or	HCV	RNA	was	unquantifiable	and	the	lower	limit	of	
quantification	was	 ≤50	IU/mL	 (ie	HCV	RNA	detectable	 but	 below	
the	limit	of	quantification).
Virologic	breakthrough	was	defined	as	≥1	documented	HCV	RNA	
measurement	<50	IU/mL	 followed	 by	HCV	 RNA	≥50	IU/mL	 during	
treatment.	 Virologic	 relapse	 was	 defined	 as	 HCV	 RNA	<50	IU/mL	
at	EOT	followed	by	post-	treatment	HCV	RNA	≥50	IU/mL	in	patients	
who	completed	treatment	(not	shortened	by	more	than	7	days)	(see	
Supplementary	Materials	for	missing	values	imputation.)
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Demographics	and	clinical	characteristics	were	assessed	at	base-
line.	Patient-	reported	comedication	use	during	treatment	was	eval-
uated.	The	administration	of	any	oral	or	injected	medications,	which	
were	taken	at	the	time	when	the	decision	was	made	to	initiate	DAA	
treatment	until	 after	 the	 last	DAA	dose,	was	documented	 (includ-
ing	opiate	substitution,	contraceptives/hormonal	replacements	and	
herbal	supplements)	 (see	Supplementary	Materials	 for	 information	
on	comedication	coding).
The	management	profiles	of	commonly	used	comedications	with	
potential	 DDIs	 with	 DAAs	 within	 the	 following	 disease-	indicated	
drug	classes	were	evaluated	(all	drugs	within	each	class	were	consid-
ered):	drugs	for	peptic	ulcers	and	gastro-	esophageal	reflux	disease	
(GERD),	cholesterol-	lowering	drugs	(statins),	antipsychotic	drugs	and	
antiepilepsy	drugs	(see	Table	S1	for	the	list	of	drugs	in	each	class).	
Changes	in	the	management	profiles	of	patients’	comedications	be-
fore	or	during	DAA	treatment	were	classified	according	to	the	fol-
lowing categories:
•	 comedication	maintained	without	change	(dose	modifications	or	
temporary	interruptions	were	not	documented);
•	 permanently	 discontinued	 before	 or	 during	 DAA	 treatment,	 or	
subsequently	resumed	post-treatment;
•	 comedication	was	permanently	or	temporarily	replaced	or	a	sub-
stitute drug used at the start of or during treatment;
• new comedications were introduced during treatment.
Safety	was	assessed	at	each	visit	using	the	incidence	of	adverse	
events	(AEs)	and	abnormal	laboratory	measurements.	All	treatment-	
emergent	AEs	were	collected	with	onset	between	 treatment	 initia-
tion	and	EOT	(or	treatment	initiation	plus	planned	treatment	duration	
when	 treatment	 end	was	missing)	 plus	 30	days	 post-	treatment,	 in-
cluding	AEs	with	missing	onset	date	and	treatment-	related	AEs	irre-
spective	of	onset.	AEs	were	reported	by	the	investigator	and	coded	
according	to	MedDRA	(Medical	Dictionary	for	Regulatory	Activities,	
McLean,	VA,	USA)	system	organ	class	and	preferred	terms	(versions	
18.0,	19.0,	19.1,	20.0	and	20.1).	Abnormal	laboratory	measurements	
were	evaluated	 in	patients	with	known	treatment	end	date	and	≥	1	
post-	nadir	visit	for	alanine	aminotransferase	(ALT)	or	aspartate	trans-
aminase	(AST),	and	≥	1	post-	baseline	measurement	for	haemoglobin	
and	creatinine	clearance	(CrCl).	The	maximum	grades	at	any	post-	nadir	
visit	(including	baseline)	for	ALT	and	AST	or	any	post-	baseline	visit	(re-
gardless	of	the	baseline	value)	for	haemoglobin	and	CrCl	through	to	
EOT	were	summarized	(see	Table	S2A	for	severity	grades).
2.4 | Statistical analysis
Demographics	 and	 baseline	 characteristics,	 including	 comorbidi-
ties,	 for	 the	 core	 population	 were	 summarized	 descriptively.	 The	
percentage	of	patients	who	achieved	SVR12	was	evaluated	 in	 the	
CPSFU	population	and	stratified	by	genotype	(or	subtype),	cirrhosis	
status,	comorbidity,	prior	HCV	treatment	experience	and	according	
to	RBV	coadministration.	SVR12	rates	were	also	assessed	in	patients	
who	completed	their	full	course	of	treatment	 (ie	not	shortened	by	
more	 than	7	days).	 In	each	case,	2-	sided	95%	confidence	 intervals	
(CI)	for	the	binomial	proportion	were	calculated	using	Wilson's	score	
method.	All	 treatment-	emergent	AEs	and	 laboratory	abnormalities	
were	 assessed	 in	 the	 safety	 population	 and	were	 summarized	de-
scriptively.	Common	treatment-	emergent	AEs	were	defined	as	those	
reported	in	≥5%	of	patients	at	the	preferred	term	level.	Comedication	
use	during	the	DAA-	treatment	period	and	changes	in	comedication	
management	were	 summarized	 descriptively	 for	 the	 safety	 popu-
lation.	Multiple	 treatments	were	possible	per	patient.	Patients	 re-
porting	the	use	of	more	than	1	comedication	for	a	given	drug	class	
or	treatment	management	profile	were	counted	only	once	for	that	
combination.	All	 statistical	 analyses	were	 conducted	by	Prometris	
GmbH	(Mannheim,	Germany)	using	the	SAS®	software	package	(ver-
sion	9.4;	SAS	Institute	Inc.,	Cary,	NC,	USA).
3  | RESULTS
This	pooled	analysis	 included	patient-	level	data	from	289	sites.	Of	
these,	98%	were	based	in	urban	locations	and	most	sites	were	either	
academic	or	university	hospitals	(39%),	or	private	practices	or	hos-
pitals	 (33%)	 (Figure	S1A).	Most	principal	 investigators	 at	 each	 site	
were	 either	 hepatologists	 (69%)	 and/or	 gastroenterologists	 (53%)	
(Figure	S1B).	In	terms	of	patient	visits	per	month,	19%	of	sites	saw	
<25	HCV-	infected	patients	and	37%	saw	between	25	and	50	HCV-	
infected	patients.
The	 date	 of	 the	 first	 patient	 visit	 was	 6	October	 2015.	 As	 of	 
19	February	2018,	4088	patients	were	enrolled	 in	 this	study;	238	
patients	were	excluded,	and	3850	met	the	criteria	for	inclusion	in	the	
safety	population.	One	GT4-	infected	patient	from	the	safety	popula-
tion	who	had	unconfirmed	chronic	HCV	infection	was	excluded	from	
the	core	and	CPSFU	populations.	After	 applying	 further	exclusion	
criteria,	3808	and	3546	patients	 remained	 in	 the	core	and	CPSFU	
populations,	respectively	(Figure	S2).
3.1 | Baseline demographics and clinical 
characteristics
In	 the	 core	 population,	 2034	 patients	 (53%)	 were	 male,	 3375	
(89%)	were	white,	and	the	median	age	was	57	years	(range	18-	90)	
(Table	1).	A	 total	 of	 732	patients	 (19%)	 had	HCV	GT1a	 (including	
11	patients	with	GT1a/GT1b,	16	patients	with	GT1	unknown	sub-
type	and	two	patients	with	GT1	unknown	subtype/GT4	unknown	
subtype),	2619	(69%)	had	GT1b	(including	one	patient	with	GT1b/
GT4	unknown	subtype),	and	457	(12%)	had	GT4	(non-	GT1).	The	dis-
tribution	of	HCV	GT1	and	GT4	for	each	country	is	shown	in	Figure	
S3,	and	only	Kuwait	had	a	greater	percentage	of	patients	infected	
with	 GT4	 than	 GT1	 (69%	 versus	 31%).	 A	 total	 of	 1319	 patients	
(35%)	had	cirrhosis:	133	GT1a-	infected	patients	(18%);	1074	GT1b-	
infected	patients	 (41%);	112	GT4-	infected	patients	 (25%).	 In	1469	
patients	(39%)	who	had	prior	treatment	experience,	1181	patients	
(81%)	had	 received	pegylated	 interferon	alfa	as	 their	most	 recent	
prior	antiviral	treatment;	a	further	252	patients	(17%)	had	received	
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pegylated	 interferon	 (not	 specified),	 interferon	 alfa	 or	 interferon	
(not	 specified).	 Prior	 DAA	 treatment	 was	 taken	 by	 162	 patients	
(11%).	Regarding	current	DAA	regimens,	most	patients	received	12-	
week	regimens:	654	GT1a-	infected	patients	 (89%)	 received	OBV/
PTV/r	+	DSV	+	RBV;	 1773	 GT1b-	infected	 patients	 (68%)	 received	
OBV/PTV/r	+	DSV	and	737	GT1b-	infected	patients	(28%)	received	
OBV/PTV/r	+	DSV	+	RBV;	 and	 424	 GT4-	infected	 patients	 (93%)	
received	 OBV/PTV/r	+	RBV	 (Table	1).	 Overall,	 89	 GT1b-	infected	
patients	 (3%)	 received	planned	 treatment	 for	8	weeks	with	OBV/
PTV/r	+	DSV	 without	 RBV	 (fibrosis	 scores:	 F0-	F1,	 n	=	69	 [84%];	
F2,	n	=	11	 [13%];	F3,	n	=	2	 [2%];	missing,	n	=	7;	 see	Table	S2B	 for	
criteria	used	to	assess	overall	liver	fibrosis	stage).	Overall,	RBV	was	
coadministered	to	1892	patients	(50%).	More	than	1	comorbidity	was	
present	in	2549	patients	(67%;	Table	1).	The	prevalence	of	renal	im-
pairment	(according	to	CTCAE	grading)	was	as	follows:	2640	patients	
(78%)	had	Grade	0;	409	patients	(12%)	had	Grade	1;	278	patients	(8%)	
had	Grade	2;	27	patients	(1%)	had	Grade	3;	and	41	patients	(1%)	had	
Grade	4	(413	patients	had	missing	data).
3.2 | Virologic response
The	 overall	 SVR12	 rate	 in	 the	 CPSFU	 (whole	 cohort)	 was	 95.9%	
(n/N	=	3401/3546;	95%	CI	95.2-	96.5).	The	SVR12	rate	was	96.2%	
(n/N	=	3009/3129;	 95%	 CI	 95.4-	96.8)	 in	 GT1-	infected	 patients	
(GT1a:	 92.6%	 [n/N	=	603/651;	 95%	 CI	 90.4-	94.4];	 GT1b:	 97.1%	
[n/N	=	2406/2478;	95%	CI	96.4-	97.7]).	The	SVR12	rate	was	94.0%	
(n/N	=	392/417;	95%	CI	91.3-	95.9)	in	GT4-	infected	patients.	SVR12	
rates	 stratified	 by	 HCV	 genotype/subtype	 and	 baseline	 cirrhosis	
TABLE  1 Baseline	demographics	and	clinical	characteristics	
(core	population)
Characteristic
Total 
N = 3808
Male 2034	(53)
Age,	median	(range),	years 57	(18-	90)
 >65 years 871	(23)
Race
	White/Caucasian 3375	(89)
BMI,	mean	(SD),	kg/m2 26.5	(4.7)
HCV	genotype
 1a 697	(18)
 1a/1b 11	(<1)
 1b 2618	(69)
	1	other/unknown 25	(<1)
	4 157	(4)
	4	unknown 300	(8)
HCV	RNA	level,	mean	(SD),	×106	IU/mL 2.1	(4.7)
Human	immunodeficiency	virus	coinfection 99	(3)
Hepatitis	B	virus	coinfection 53	(1)
Cirrhosis	status
	No	cirrhosis 2011	(53)
	Transition	to	cirrhosis 478	(13)
	Cirrhosis 1319	(35)
History	of	liver	decompensation
	No,	never	decompensated 3717	(98)
	Yes,	but	currently	compensated 70	(2)
	Currently	decompensateda 20	(<1)
 Missing, n 1
Chronic	kidney	disease 121	(3)
Previous	HCV	treatment
	Naïve 2339	(61)
	Experienced 1469	(39)
Comorbidities	(≥1)b 2549	(67)
	Cardiovascular	disease 1184	(31)
	Diabetes	mellitus 487	(13)
	Liver	and/or	CHC-	related	comorbidities 477	(13)
	Psychiatric	disorders 434	(11)
	Psychoactive	substance	dependencyc 295	(8)
	Hypothyroidism	 264	(7)
Treatment	regimen	(planned	duration)d
	GT1ae	(N	=	732)
	OBV/PTV/r	+	DSV	without	RBV	(8	weeks) 1	(<1)
	OBV/PTV/r	+	DSV	without	RBV	(12	weeks) 41	(6)
	OBV/PTV/r	+	DSV	with	RBV	(12	weeks) 654	(89)
	OBV/PTV/r	+	DSV	with	RBV	(24	weeks) 36	(5)
	GT1b	(N	=	2619)
	OBV/PTV/r	+	DSV	without	RBV	(8	weeks) 89	(3)
(Continues)
Characteristic
Total 
N = 3808
	OBV/PTV/r	+	DSV	without	RBV	(12	weeks) 1773	(68)
	OBV/PTV/r	+	DSV	without	RBV	(24	weeks) 2	(<1)
	OBV/PTV/r	+	DSV	without	RBV	(missing) 10	(<1)
	OBV/PTV/r	+	DSV	with	RBV	(12	weeks) 737	(28)
	OBV/PTV/r	+	DSV	with	RBV	(24	weeks) 8	(<1)
	GT4	(N	=	457)
	OBV/PTV/r	with	RBV	(12	weeks) 424	(93)
	OBV/PTV/r	with	RBV	(24	weeks) 24	(5)
	OBV/PTV/r	+	DSV	with	RBV	(12	weeks) 9	(2)
Data	 are	n	 (%)	unless	 stated	otherwise.	Percentages	 are	based	on	pa-
tients with valid values.
BMI,	 body	mass	 index;	 CHC,	 chronic	 hepatitis	 C;	DSV,	 dasabuvir;	GT,	
genotype;	HCV,	hepatitis	C	virus;	OBV,	ombitasvir;	PTV/r,	paritaprevir/
ritonavir;	RBV,	ribavirin;	RNA,	ribonucleic	acid;	SD,	standard	deviation.
aPatients	with	a	Child-	Pugh	score	≥7	are	defined	as	patients	with	 liver	
decompensation.	
bComorbidities	 with	 prevalence	 ≥5%	 included.	 975	 patients	 (26%)	 re-
ported	comorbidities	that	could	not	be	further	specified	in	the	electronic	
case	report	form.	
cIncluded	opioid	substitution	therapy,	n	=	235	(6%).	
dPercentages	based	on	total	number	of	patients	by	HCV	genotype.	
eIncludes	all	GT1	patients	except	patients	with	GT1b	or	GT1b/GT4.	
TABLE  1  (Continued)
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status	are	shown	in	Figure	1A.	The	overall	SVR12	rates	in	patients	
with	or	without	cirrhosis	were	96%	for	both	subgroups.
SVR12	rates	in	patients	treated	according	to	label-	recommended	
regimens	 are	 shown	 in	 Figure	 S4.	 In	 patients	 infected	with	 GT1a	
treated	 with	 OBV/PTV/r	+	DSV	+	RBV	 for	 planned	 durations	 of	
12	or	24	weeks,	SVR12	rates	were	93.3%	(n/N	=	544/583;	95%	CI	
91.0-	95.1)	and	82.4%	(n/N	=	28/34;	95%	CI	66.5-	91.7),	respectively.	
In	 patients	 infected	 with	 GT1b	 treated	 with	 OBV/PTV/r	+	DSV	
for	 planned	durations	of	 8	or	12	weeks,	 SVR12	 rates	were	96.3%	
(n/N	=	79/82;	95%	CI	89.8-	98.7)	and	96.7%	(n/N	=	1600/1654;	95%	
CI	 95.8-	97.5),	 respectively.	 In	 patients	 infected	 with	 GT4	 treated	
with	OBV/PTV/r	+	RBV	for	a	planned	duration	of	12	weeks,	SVR12	
was	94.0%	(n/N	=	362/385;	95%	CI	91.2-	96.0).	SVR12	rates	 in	pa-
tients	who	deviated	from	label-	recommended	regimens	are	shown	
in	Figure	S5.
In	 the	 CPSFU,	 145	 patients	 (4.1%)	 had	 virologic	 nonresponse	
(Table	2).	 The	 reasons	 for	 nonresponse	 were	 as	 follows:	 39	 pa-
tients	 (1.1%)	had	on-	treatment	virologic	 failure;	39	patients	 (1.1%)	
had	post-	treatment	 virologic	 relapse;	 24	patients	 (<1.0%)	 died;	 30	
patients	 (<1.0%)	 prematurely	 discontinued	 treatment	 with	 no	 on-	
treatment	virologic	failure;	13	patients	(<1.0%)	had	insufficient	viro-
logic	response	for	other	reasons.
In	 patients	with	 prior	 HCV	 treatment	 experience	 (Figure	1B),	
the	 SVR12	 rate	was	96.4%	 (n/N	=	1201/1246;	 95%	CI	 95.2-	97.3)	
in	 GT1-	infected	 patients	 (GT1a:	 91.8%	 [n/N	=	178/194;	 95%	 CI	
87.0-	94.9;	GT1b:	97.2%	[n/N	=	1023/1052;	95%	CI	96.1-	98.1]).	The	
SVR12	rate	was	92.4%	(n/N	=	145/157;	95%	CI	87.1-	95.6)	in	GT4-	
infected	patients.	 In	HCV	 treatment–experienced	patients,	 those	
infected	 with	 GT1a	 with	 cirrhosis	 tended	 to	 have	 lower	 SVR12	
rates	than	patients	without	cirrhosis,	although	the	number	of	pa-
tients	with	cirrhosis	was	comparatively	small.	Four	GT1a-	infected	
patients	with	cirrhosis	had	virologic	failure,	which	occurred	in	two	
patients	at	EOT	and	two	patients	at	the	SVR12	visit;	a	fifth	patient	
prematurely	 discontinued	 treatment	 after	 15	days	 because	 of	 an	
AE	and	had	no	post-	baseline	measurements;	and	one	patient	died	
(this	 patient	 had	 a	 planned	 treatment	 duration	 of	 24	weeks	 and	
stopped	treatment	prematurely	on	Day	147	due	to	an	AE).	SVR12	
rates	in	patients	with	or	without	RBV	coadministration	are	shown	
in	Figure	1C	and	were	≥89%	irrespective	of	HCV	genotypes/sub-
types	or	cirrhosis	status.
In	patients	with	more	than	1	comorbidity	at	baseline,	the	SVR12	
rate	was	 95.5%	 (n/N	=	2270/2378;	 95%	CI	 94.5-	96.2),	 and	 96.8%	
(n/N	=	1131/1168;	95%	CI	95.7-	97.7)	in	patients	with	no	comorbidi-
ties	at	baseline.	The	SVR12	rates	ranged	from	87.5%	to	97.1%	across	
the	comorbidity	subgroups	(Figure	1D).	The	SVR12	rates	in	patients	
with	and	without	renal	impairment	(according	to	baseline	CrCl)	are	
shown	in	Figure	S6.	High	SVR12	rates	(>92%)	were	observed	in	all	
subgroups	except	for	patients	with	Grade	3	renal	impairment,	who	
had	an	SVR12	rate	of	84%	(n/N	=	21/25).	This	subgroup	had	a	rela-
tively	small	number	of	patients,	of	which	four	patients	(GT1b,	n	=	3;	
GT4,	 n	=	1)	 discontinued	 treatment	 early	 because	 of	 AEs	with	 no	
HCV	 RNA	 collected	 after	 DAA	 treatment	 (two	 patients	 received	
RBV).
Overall,	 97%	 of	 patients	 in	 the	 CPSFU	 completed	 the	 treat-
ment	regimen.	The	overall	SVR12	rate	was	97.2%	in	these	patients	
(n/N	=	3357/3453;	95%	CI	96.6-	97.7).	In	this	population,	39	patients	
(1.1%)	had	virologic	 relapse,	31	patients	 (<1.0%)	had	on-	treatment	
virologic	 failure,	 13	 patients	 (<1.0%)	 had	 insufficient	 virologic	 re-
sponse,	and	13	patients	(<1.0%)	died.
3.3 | Management of comedications
In	 the	 safety	 population,	 58%	 of	 patients	 (n/N	=	2237/3850)	 re-
ceived	≥1	comedication	during	the	treatment	period.	The	most	com-
monly	used	drug	classes	(in	>5%	of	patients)	were	β-	blockers	(15%;	
n	=	564),	analgesics	(11%;	n	=	430),	and	drugs	for	peptic	ulcers	and	
GERD	 (10%;	n	=	394)	 (Table	S3A).	The	 three	most	commonly	used	
drugs	(in	≥2%	of	patients)	were	levothyroxine	(7%;	n	=	257),	acetyl-
salicylic	acid	(6%;	n	=	214)	and	amlodipine	(6%;	n	=	214)	(Table	S3B).	
Based	 on	 information	 available	 at	 https://www.hep-druginterac-
tions.org/,21 none of these commonly used drugs were contraindi-
cated	 for	 use	with	OBV/PTV/r	±	DSV	 and	 seven	medications	 had	
established	 or	 potentially	 clinically	 relevant	 DDIs	 (levothyroxine,	
amlodipine,	 bisoprolol,	 pantoprazole,	 furosemide,	 indapamide	 and	
omeprazole;	Table	S3B).
Comedication	use	was	continued	for	the	entire	duration	of	OBV/
PTV/r	±	DSV	±	RBV	 treatment	 in	 the	 majority	 of	 patients.	 Of	 the	
patients	who	took	≥1	drug	prior	to	or	during	DAA	treatment,	2116	
continued	taking	≥1	comedication	(92%;	n/N	=	2116/2296),	whereas	
94	patients	permanently	discontinued	their	comedications	prior	to	
DAA	 treatment	 and	 84	 discontinued	 their	 comedications	 during	
DAA	 treatment	 (<5%	 for	 each).	 Comedications	were	 discontinued	
prior	to	the	 initiation	of	OBV/PTV/r	±	DSV	±	RBV	treatment	and	
subsequently	 resumed	 post-	treatment	 without	 replacement	 in	
225	 patients	 (10%).	 Comedications	 were	 introduced	 during	 the	
course	of	DAA	treatment	in	374	patients	(10%).	Less	than	4%	of	
patients	had	their	comedication	replaced	(n	=	48)	or	used	a	substi-
tute	drug	(n	=	47)	during	OBV/PTV/r	±	DSV	±	RBV	treatment.
3.3.1 | Management profiles for specific 
comedications
The	management	profiles	 for	 specific	 comedications	 that	are	con-
sidered	 to	 have	 a	 high	 DDI	 potential	 are	 shown	 in	 Figure	 S7.	 In	
the	overall	population,	417	patients	 (11%)	 received	drugs	 for	pep-
tic	 	ulcers	and	GERD,	95	patients	 (2%)	 received	antiepilepsy	drugs,	
and	90	patients	 (2%)	 received	antipsychotic	drugs	prior	 to	or	dur-
ing	 OBV/PTV/r	±	DSV	±	RBV	 treatment.	 The	 majority	 of	 patients	
(80%-	93%;	four	patients	had	no	profile	reported)	maintained	these	
comedications	without	change	(ie	no	comedication	discontinuation,	
replacement,	 substitution	 or	 introduction)	 throughout	 DAA	 treat-
ment	(Figure	S7).	A	total	of	123	patients	(3%)	received	statin	therapy	
during	OBV/PTV/r	±	DSV	±	RBV	treatment.	Statin	therapy	(with	ei-
ther	rosuvastatin,	atorvastatin,	pravastatin	or	simvastatin)	was	main-
tained	without	change	in	53	patients	(43%);	46	(37%)	discontinued	
statin	 therapy	 before	 DAA	 treatment	 and	 subsequently	 resumed	
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post-	treatment	 (without	 replacement);	 and	 17	 (14%)	 permanently	
discontinued	statin	therapy	before	or	during	DAA	treatment	(with-
out	replacement).
The	SVR12	rates	in	patients	with	confirmed	use	of	drugs	for	pep-
tic	ulcers	and	GERD,	statins,	antipsychotics	or	antiepileptics	during	
OBV/PTV/r	±	DSV	±	RBV	 treatment	 versus	 those	 who	 had	 never	
F IGURE  1 SVR12	rates	by	HCV	genotype/subtype	and	cirrhosis	status	in	(A)	the	overall	population,	(B)	patients	with	prior	treatment	
experience,	(C)	by	ribavirin	treatment	(CPSFU	population)	and	(D)	by	baseline	comorbidity	subgroups.	Error	bars	represent	95%	confidence	
intervals.	†Patients	infected	with	GT1a	include	those	with	other/unknown	subtypes	except	G1b.	CPSFU,	core	population	with	sufficient	
follow-	up;	GT,	genotype;	HCV,	hepatitis	C	virus;	RBV,	ribavirin;	SVR12,	sustained	virologic	response	at	post-	treatment	Week	12
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used	 these	drugs	before	or	during	OBV/PTV/r	±	DSV	±	RBV	 treat-
ment	are	shown	in	Figure	S8.	The	SVR12	rates	in	patients	who	used	
these	drug	classes	ranged	from	90%	to	95%.	The	SVR	rate	in	patients	
who	did	not	use	the	respective	drug	class	was	96%	in	each	case.
3.4 | Safety
In	the	safety	population	(N	=	3850),	1008	patients	(26.2%)	reported	
≥1	 treatment-	emergent	AE	 (Table	3).	The	most	common	AEs	were	
fatigue	 (n	=	246;	 6.4%)	 and	 anaemia	 (n	=	202;	 5.2%).	 Treatment-	
emergent	serious	AEs	occurred	in	129	patients	(3.4%),	with	anaemia	
(n	=	15;	0.4%),	hepatic	failure	(n	=	7;	0.2%),	hepatocellular	carcinoma	
(n	=	5;	0.1%)	and	jaundice	(n	=	4;	0.1%)	being	the	most	frequently	re-
ported	serious	AEs.	The	incidence	of	anaemia	was	most	frequently	
reported	in	patients	who	received	RBV.
The	total	number	of	deaths	reported	was	32.	Treatment-	emergent	
AEs	 leading	to	death	occurred	 in	14	patients.	The	AEs	reported	for	
these	 patients	 were	 cardiac	 failure	 (n	=	1),	 cardiopulmonary	 failure	
(n	=	1),	 myocardial	 infarction	 (n	=	1),	 gastrointestinal	 haemorrhage	
(n	=	1),	 oesophageal	 variceal	 haemorrhage	 (n	=	1),	 decompensated	
liver	cirrhosis	(n	=	1),	hepatic	failure	(n	=	1),	acute	pyonephrosis	(n	=	1;	
renal	 abscess),	 sepsis	 (n	=	1;	 thoracic	 wall	 abscess	 due	 to	 immuno-
suppression),	 overdose	 (n	=	2;	 1	 patient	 had	 substance	 overdose;	 1	
patient	had	methadone	overdose),	carotid	aneurysm	rupture	 (n	=	1),	
sudden	death	(n	=	1)	and	chronic	kidney	disease	(n	=	2).
In	patients	who	received	drugs	for	peptic	ulcers	and	GERD,	an-
tiepilepsy	drugs,	antipsychotic	drugs	or	statins,	≥1	AE	was	reported	
by	 24%-	26%	 of	 patients	 who	 had	 never	 used	 these	 drugs	 before	
or	during	OBV/PTV/r	±	DSV	±	RBV	treatment,	and	by	39%-	47%	of	
patients	with	confirmed	use	of	these	drugs	during	DAA	treatment	
(Table	S4).	The	most	common	AEs	(in	≥5%	of	patients)	were	anaemia	
and	fatigue,	which	occurred	more	frequently	 in	patients	with	con-
firmed	use	of	drugs	for	peptic	ulcers	and	GERD,	statins,	and	antipsy-
chotics.	The	rates	of	these	AEs	were	similar	between	patients	using	
and	not	using	antiepileptic	drugs.
The	 incidence	 of	 post-	baseline	 Grade	 3	 or	 higher	 laboratory	
abnormalities	 reported	 was	 infrequent.	 In	 the	 overall	 population,	
Grade	3	and	4	elevations	in	ALT	levels	occurred	in	15	patients	(1.5%)	
and	2	patients	(<1.0%),	respectively.	Grade	3	elevations	in	AST	levels	
occurred	in	6	patients	(<1.0%);	no	Grade	4	elevations	were	observed.	
Grade	3	and	4	decreases	 in	haemoglobin	 levels	occurred	in	17	pa-
tients	(<1.0%)	and	1	patient	(<1.0%),	respectively.	Grade	3	and	4	de-
creases	in	CrCl	occurred	in	30	patients	(1.1%)	and	37	patients	(1.3%),	
respectively.	A	 summary	of	 laboratory	abnormalities	by	 treatment	
regimen	is	shown	in	Table	S5.
The	mean	(standard	deviation	[SD])	treatment	duration	of	OBV/
PTV/r	±	DSV	±	RBV	 regimens	 was	 84	 (15)	 days.	 Overall,	 120	 pa-
tients	(3.1%)	prematurely	discontinued	these	regimens;	the	reasons	
for	discontinuation	included	AEs	or	serious	AEs	(54	patients;	1.4%),	
patient	refusal	to	continue	treatment	(22	patients;	<1.0%),	consent	
withdrawal	 or	 lost	 to	 follow-	up	 (18	 patients;	 <1.0%),	 viral	 relapse	
or	breakthrough	(two	patients;	<1.0%)	and	other	nonsafety-	related	
reasons	(24	patients;	<1.0%).	The	mean	(SD)	duration	of	RBV	treat-
ment	was	83	(21)	days.	Treatment	with	RBV	was	discontinued	before	
termination	of	the	OBV/PTV/r	±	DSV	regimens	in	94	patients	(5.0%).	
The	 reasons	 for	 RBV	 discontinuation	 were	 anaemia	 (39	 patients;	
2.1%),	rash	(seven	patients;	<1.0%),	nausea/vomiting	(seven	patients;	
<1.0%)	and	other	reasons	(41	patients;	2.2%).
TABLE  2 Virologic	nonresponse	rates	by	HCV	genotype/subtype	and	cirrhosis	status	(CPSFU	population)
Total 
N = 3546
GT1aa
N = 651
GT1b 
N = 2478
GT4 
N = 417
Cirrhosis 
N = 1253
No cirrhosis 
N = 2293
Cirrhosis 
N = 118
No cirrhosis 
N = 533
Cirrhosis 
N = 1033
No cirrhosis 
N = 1445
Cirrhosis 
N = 102
No cirrhosis 
N = 315
Overall 55	(4) 90	(4) 13	(11) 35	(7) 35	(3) 37	(3) 7	(7) 18	(6)
On-	treatment	virologic	
failureb
13	(1) 26	(1) 3	(3) 9	(2) 7	(<1) 8	(<1) 3	(3) 9	(3)
Relapsec 11	(<1) 28	(1) 1	(<1) 14	(3) 9	(<1) 10	(<1) 1	(1) 4	(1)
Death 13	(1) 11	(<1) 2	(2) 3	(<1) 10	(1) 7	(<1) 1	(1) 1	(<1)
Premature	study	drug	
discontinuationd
13	(1) 17	(<1) 5	(4) 4	(<1) 7	(<1) 10	(1) 1	(1) 3	(1)
Insufficient	virologic	
response	reported	
(other	reasons)e
5	(<1) 8	(<1) 2	(2) 5	(<1) 2	(<1) 2	(<1) 1	(1) 1	(<1)
CPSFU,	core	population	with	sufficient	follow-	up;	EOT,	end	of	treatment;	GT,	genotype;	HCV,	hepatitis	C	virus;	RNA,	ribonucleic	acid.
aPatients	infected	with	GT1a	include	those	with	other/unknown	subtypes	except	G1b.	
bBreakthrough	(defined	as	at	least	1	documented	HCV	RNA	measurement	<50	IU/mL	followed	by	an	HCV	RNA	measurement	≥50	IU/mL	during	treat-
ment)	or	failure	to	suppress	(each	on-	treatment	HCV	RNA	measurement	≥50	IU/mL).	
cDefined	as	an	HCV	RNA	measurement	<50	IU/mL	at	EOT	followed	by	an	HCV	RNA	measurement	≥50	IU/mL	post-	treatment	in	patients	who	com-
pleted	treatment	(not	more	than	7	days	shortened).	
dWith	no	on-	treatment	virologic	failure.	
ePatients	for	whom	insufficient	virologic	response	was	reported,	or	who	had	an	HCV	RNA	measurement	≥50	IU/mL	post-	EOT	and	none	of	the	above.	
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4  | DISCUSSION
This	pooled	analysis	of	patient-	level	data	 from	post-	marketing	ob-
servational studies was conducted to evaluate the safety and ef-
fectiveness	 of	 OBV/PTV/r	±	DSV	±	RBV,	 including	 the	 impact	 of	
common comorbidities and comedications, when used in daily clini-
cal	practice	and	 in	 accordance	with	 local	 guidelines	and	 label	 rec-
ommendations.	The	results	provide	real-	world	evidence	that	these	
regimens	 are	 highly	 effective	 in	 patients	 infected	 with	 HCV	 GT1	
or	GT4.	The	SVR12	 rate	was	96%	across	 the	entire	 cohort,	which	
complements	the	high	efficacy	reported	in	pivotal	clinical	trials.7–12 
Similarly,	rates	of	on-	treatment	virologic	failure	and	post-	treatment	
relapse	(2.2%)	compare	favourably	with	those	reported	in	clinical	tri-
als.7–12,22	Common	comorbidities	had	minimal	impact	on	the	effec-
tiveness	of	OBV/PTV/r	±	DSV	±	RBV,	and	most	patients	continued	
taking	their	comedications	during	treatment.
Overall,	 SVR	 rates	 remained	 high	 regardless	 of	 cirrhosis	 sta-
tus,	 prior	 HCV	 treatment	 experience	 or	 RBV	 coadministration.	
GT1a-	infected	 patients	with	 cirrhosis	 had	 lower	 SVR12	 rates	 com-
pared	with	other	subgroups.	One	explanation	for	this	finding	is	that	
GT1a-	infected	patients	with	compensated	cirrhosis	are	eligible	for	a	
	12-	week	regimen	depending	on	their	virologic	response	to	previous	
peginterferon-	based	 treatment,	 despite	 the	 recommended	 treat-
ment	duration	of	24	weeks.1–3	However,	in	clinical	trials,	lower	SVR12	
rates	 in	 GT1a-	infected	 patients	with	 prior	 null	 response	 or	 relapse	
to	previous	HCV	treatment	were	observed	with	12	versus	24	weeks	
of	OBV/PTV/r	+	DSV	+	RBV	treatment.11	 In	GT1b-	infected	patients,	
SVR12	rates	were	not	significantly	impacted	by	cirrhosis	status,	prior	
treatment	experience	or	a	shorter	8-	week	treatment	regimen.	These	
trends	in	SVR12	rates	are	consistent	with	those	seen	in	pivotal	clinical	
trials.7–9,11,12,20	Similarly,	in	GT4-	infected	patients,	SVR12	rates	com-
pared	favourably	with	those	seen	in	clinical	trials	(94%-	100%).10,23,24
As	 expected,	 most	 patients	 had	 ≥1	 comorbidity	 and	 SVR12	
rates	 were	 numerically	 similar	 between	 patients	 with	 versus	
without	 comorbidities	 (95%	 vs	 97%).	 SVR12	 rates	 ranged	 from	
88%	to	97%	across	all	evaluated	comorbidity	subgroups,	suggest-
ing	comorbidities	had	minimal	impact	on	the	effectiveness	of	OBV/
PTV/r	±	DSV	±	RBV.	Clinically	relevant	subgroups	such	as	patients	
receiving	opioid	substitution	therapy	or	with	psychiatric	disorders	
have	faced	significant	barriers	to	HCV	therapy	because	of	concerns	
regarding	poor	adherence	to	treatment,	HCV	reinfection	and	AEs.25 
The	recent	availability	of	highly	effective	DAA	therapies	and	inte-
grated	 approaches	 to	 care	management	 have	 increased	 the	 rates	
of	successful	HCV	treatment	in	these	populations.26	In	this	analy-
sis,	SVR12	rates	in	these	subgroups	were	comparable	to	the	overall	
population.	This	was	also	true	for	patients	with	renal	 impairment,	
consistent with the clinical trial results27	 and	 other	 real-	world	
studies.9,28
As	a	result	of	the	high	prevalence	of	comorbid	conditions	in	HCV-	
infected	patients,	comedications	are	frequently	prescribed,	many	of	
which	have	the	potential	to	interact	with	DAA	drugs.17,29	DDIs	can	
negatively	impact	a	drug's	therapeutic	efficacy	and	therefore	have	
important	implications	for	routine	clinical	care.	All	recently	approved	
DAA	 therapies	 interact	 with	 drug-	metabolizing	 enzymes	 or	 drug	
transporters.	 Careful	 pretreatment	 screening	 for	 potential	 DDIs,	
using	resources	such	as	the	University	of	Liverpool	website	(www.
hep-druginteractions.org),21	can	help	guide	clinicians	prescribe	the	
most	appropriate	regimen.	HCV	treatment	guidance	recommends	all	
patients	 are	assessed	 for	 comorbidities	 and	potential	DDIs	before	
undergoing	 DAA	 treatment,	 and	 before	 starting	 other	 comedica-
tions	 during	DAA	 treatment.5,6	OBV/PTV/r	±	DSV-	based	 regimens	
are contraindicated for coadministration with drugs that are highly 
dependent	on	CYP3A	for	clearance,	strong	inducers	of	CYP3A	and	
CYP2C8,	and	strong	inhibitors	of	CYP2C8.1–4
Studies	 in	 large	 real-	world	 cohorts	 have	 shown	 that	 a	 signifi-
cant	number	of	patients	 receiving	comedications	and	treated	with	
OBV/PTV/r	±	DSV	±	RBV	 are	 potentially	 at	 risk	 for	 DDIs.17,29	 In	
the	 present	 study,	 more	 than	 half	 of	 the	 patients	 (58%)	 received	
TABLE  3 Summary	of	treatment-	emergent	AEs	by	treatment	regimen	(safety	population)
Adverse event
OBV/PTV/r  
N = 20
OBV/PTV/r + RBV 
N = 455
OBV/PTV/r + DSV 
N = 1930
OBV/PTV/r + DSV + RBV 
N = 1445
Cirrhosis 
N = 2
No cirrhosis 
N = 18
Cirrhosis 
N = 114
No cirrhosis 
N = 341
Cirrhosis 
N = 433
No cirrhosis 
N = 1495
Cirrhosis 
N = 785
No cirrhosis 
N = 660
At	least	1	AE 2	(100) 4	(22) 37	(32) 96	(28) 103	(24) 331	(22) 209	(27) 225	(34)
Serious	AEs 0 0 8	(7) 6	(2) 24	(6) 28	(2) 40	(5) 23	(3)
AEs	leading	to	
death
0 0 1	(<1) 0 2	(<1) 1	(<1) 6	(<1) 4	(<1)
Common	AEs	(in	≥5%	of	patients)a
 Anaemia 0 0 18	(16) 28	(8) 1	(<1) 2	(<1) 95	(12) 58	(9)
	Fatigue 0 1	(6) 8	(7) 22	(6) 17	(4) 103	(7) 28	(4) 67	(10)
Data	are	n	(%).	AEs	with	onset	between	treatment	initiation	and	end	of	treatment	(or	treatment	initiation	plus	planned	treatment	duration	when	treat-
ment	end	was	missing)	plus	30	days	post-	treatment,	including	AEs	with	missing	onset	date	and	treatment-	related	AEs	irrespective	of	onset.
AE,	adverse	event;	DSV,	dasabuvir;	OBV;	ombitasvir;	PTV/r,	paritaprevir/ritonavir;	RBV,	ribavirin.
aAt	the	preferred	term	level;	≥5%	of	patients	in	the	total	safety	population	(N	=	3850).	
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≥1	 comedication	 during	 the	 treatment	 period.	 None	 of	 the	 most	
commonly used comedications were contraindicated, although 7 
had	clinically	relevant	DDIs.	Nevertheless,	>90%	of	patients	taking	
comedications continued to receive at least 1 of their drugs during 
treatment.	We	specifically	evaluated	the	treatment	profiles	of	drugs	
for	peptic	ulcers	and	GERD,	statins,	antiepileptics	and	antipsychot-
ics because these drug classes include several medications that are 
either	 contraindicated	 and/or	 have	 established	 DDIs	 with	 OBV/
PTV/r	±	DSV	and	are	therefore	considered	more	difficult	to	manage.	
Although	AE	rates	were	higher	in	patients	who	had	confirmed	use	of	
these	drug	classes	during	OBV/PTV/r	±	DSV	±	RBV	 treatment	ver-
sus	 those	who	had	never	used	 these	drugs	before	or	during	DAA	
treatment,	most	patients	continued	to	receive	these	comedications	
throughout	DAA	treatment,	with	appropriate	adjustments	made	to	
their	management.	Consistent	with	their	widespread	use	in	the	gen-
eral	population,	drugs	for	peptic	ulcers	and	GERD	were	frequently	
used	in	this	population	(10%	of	patients).	Furthermore,	despite	the	
established	DDI	between	omeprazole	and	OBV/PTV/r	±	DSV,	which	
results	in	a	decrease	in	omeprazole	concentration	(but	no	effect	on	
DAA	component	concentrations),1	most	patients	maintained	this	co-
medication	class	without	change,	and	the	SVR12	rate	 remained	at	
95%,	 suggesting	 that	 acid-	related	 symptoms	were	well	 controlled.	
Overall,	the	use	of	statins,	antipsychotics	or	antiepileptics	was	low	
in	this	patient	cohort	(≤3%	for	each	class)	and	their	use	was	associ-
ated	with	small	decreases	 in	SVR12	rates	versus	patients	who	did	
not	 use	 these	 drugs	 before	 or	 during	 DAA	 treatment	 (90%-	92%	
vs	 96%).	 However,	 more	 than	 half	 of	 the	 patients	 taking	 statins	
required	 adjustments	 before	 or	 during	 OBV/PTV/r	±	DSV	±	RBV	
treatment.	These	adjustments	are	consistent	with	drug	labelling	for	
OBV/PTV/r	±	DSV,	which	stipulates	that	members	of	the	statin	class	
are	 either	 contraindicated	 (lovastatin,	 atorvastin	 and	 simvastin)	 or	
should	be	used	at	reduced	doses	(rosuvastatin	and	pravastatin)	be-
cause	of	possible	DDIs	leading	to	increases	in	statin	concentrations	
and	the	potential	for	myopathy.1–4	The	antipsychotic	and	antiepilep-
tic classes also include several drugs that are contraindicated with 
OBV/PTV/r	±	DSV.	The	antiepileptic	drugs	carbamazepine,	phenyt-
oin	and	phenobarbital	may	decrease	exposures	of	OBV,	PTV,	DSV	
and	ritonavir	 (via	CYP3A4	 induction),	 leading	 to	a	potential	 loss	 in	
anti-	HCV	therapeutic	activity	and	therefore	must	not	be	coadminis-
tered.1–4	Exposures	to	the	antipsychotic	drugs	lurasidone,	pimozide	
or	 quetiapine	 may	 be	 increased	 when	 coadministered	 with	 OBV/
PTV/r	±	DSV	(via	CYP3A4	inhibition	by	ritonavir),	potentially	leading	
to	serious	or	life-	threatening	adverse	reactions.1–4	Overall,	however,	
more	 than	 80%	 of	 patients	 continued	 to	 receive	 each	 drug	 class	
without change to their management.
The	 overall	 incidence	 of	 treatment-	emergent	 AEs	 (26%)	 was	
considerably	lower	than	that	seen	in	pivotal	clinical	trials	of	OBV/
PTV/r	±	DSV-	based	 regimens	 (67%-	92%),	 suggesting	 that	 safety	
outcomes	may	have	been	underreported	in	this	real-	world	study.	
The	 incidence	of	 serious	AEs	 (3%)	was	 consistent	with	 rates	 re-
ported	 in	clinical	 trials.7–12	No	new	or	unexpected	AEs	were	ob-
served,	and	fatigue	and	anaemia	were	the	only	AEs	that	occurred	
in	>5%	 of	 the	 overall	 population.	 As	 expected,	 the	 incidence	 of	
anaemia	was	more	frequent	 in	patients	who	received	RBV	in	the	
present	 study	 and	was	 the	main	 reason	 for	 patients	 discontinu-
ing	 RBV	 treatment	 before	 terminating	 OBV/PTV/r	±	DSV	+	RBV	
regimens.	 Low	 rates	 (3.1%)	 of	 DAA	 drug	 discontinuation	 were	
observed,	consistent	with	the	rates	in	clinical	trials.	Similarly,	the	
incidence of laboratory abnormalities was largely in accordance 
with that seen in clinical trials.7–12
The	number	of	large	real-	world	studies	of	OBV/PTV/r	±	DSV	±	RBV	
regimens	 in	 routine	 clinical	 practice	 is	 currently	 limited.	 Clinical	
	practice	data	from	the	German	Hepatitis	C	Registry,	which	included	
558	 patients	 treated	 with	 OBV/PTV/r	±	DSV	±	RBV,	 showed	 that	
SVR12	rates	were	96%	in	GT1-	and	100%	in	GT4-	infected	patients,	
regardless	of	 cirrhosis	 status	or	prior	 antiviral	 treatment.30	The	 in-
cidence	of	AEs	and	serious	AEs	were	52%	and	2%,	 respectively.	A	
meta-	analysis	of	real-	world	data	from	5726	patients	receiving	OBV/
PTV/r	±	DSV-	based	 regimens	 showed	 that	 5548	 patients	 achieved	
SVR12	(97%),	regardless	of	cirrhosis	status.31	The	rate	of	discontinu-
ations	attributable	to	AEs	was	≤3%,	and	the	incidence	of	serious	AEs	
was	≤5%.	Another	similar	meta-	analysis	of	real-	world	data	from	5158	
OBV/PTV/r	±	DSV	±	RBV-	treated	patients	(20	cohorts	from	12	coun-
tries)	reported	SVR12	rates	of	≥94%	in	HCV	GT1-	or	GT4-	infected	pa-
tients.32	SVR12	rates	in	patients	with	or	without	cirrhosis	and	by	prior	
antiviral	treatment	were	generally	similar	across	HCV	genotypes/sub-
types.	An	analysis	of	150	treatment-	naïve	patients	from	the	Spanish	
Hepa-	C	registry	who	were	infected	with	GT1b	and	treated	with	OBV/
PTV/r	+	DSV	for	8	weeks	showed	high	SVR12	rates	(97%),	with	no	se-
rious	AEs	or	treatment	discontinuations	reported.33	Large	real-	world	
effectiveness	studies	from	the	US	Veterans’	Affairs	National	Health	
Care	System	have	 reported	overall	 SVR12	 rates	 in	 the	 range	86%-	
95%	in	GT1-	infected	patients	treated	with	OBV/PTV/r	±	DSV-	based	
regimens,	which	 is	 approaching	 the	 rate	 seen	 in	 clinical	 trials.34–36 
Lower	SVR12	rates	in	this	US	Veteran	population	are	not	unexpected	
because	these	patients	tend	to	have	a	high	prevalence	of	comorbid-
ities	 that	have	historically	been	considered	difficult	 to	 treat.	Other	
real-	world	studies	of	OBV/PTV/r	±	DSV-	based	regimens	have	shown	
SVR12	rates	that	are	equivalent	to	the	rates	seen	in	clinical	trials.37–39 
Taken	 together,	our	 results	 support	 the	accumulating	body	of	 real-	
world	 evidence	 confirming	 the	 safety	 and	 effectiveness	 of	 OBV/
PTV/r	±	DSV	±	RBV	regimens	in	routine	clinical	practice.
This	analysis	has	several	limitations.	As	with	any	real-	world	study,	
there	 is	 scope	 for	 considerable	 bias	 in	 the	 reporting	 and	 collection	
of	patient-	level	 information.	In	particular,	safety	outcomes	are	often	
limited	 by	 underreporting	 in	 the	 real-	world	 setting.	 Additionally,	
DDI	screening	prior	to	the	initiation	of	antiviral	treatment	will	often	
predicate	 the	 choice	 of	 DAA	 drug	 based	 on	 comedication	 usage.	
Nevertheless,	we	observed	 comedication	 class	 usage	 typical	 of	 the	
comorbidities	seen	in	this	real-	world	cohort.	The	reasons	for	changes	
in	comedication	management	were	not	reported;	therefore,	it	was	not	
determined whether adjustments in comedications were as a result of 
DDIs.	A	further	limitation	was	that	information	regarding	comedica-
tion	dose	modification	or	temporary	interruption	was	not	documented	
in	 patients	who	were	 classified	 as	 having	 continuous	 comedication	
treatment.	It	was	also	not	possible	to	establish	a	relationship	between	
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DDIs	and	AEs.	Finally,	some	subgroups	in	this	analysis	had	compara-
tively	 small	patient	numbers,	and	 therefore,	meaningful	 conclusions	
on	safety	and	effectiveness	cannot	be	inferred	using	these	subgroups.
Although	 several	 new	 pangenotypic	 DAA	 regimens	 are	 now	
approved	 for	 the	 treatment	 of	 chronic	 HCV	 infection,	 access	 is	
still limited for many countries.40 Until such access is achieved, 
genotype-	specific	DAAs	 such	as	OBV/PTV/r	±	DSV	±	RBV	 remain	
the	standard	of	care	treatment	for	patients	with	chronic	HCV	infec-
tion.	This	analysis	of	real-	world	data	from	a	large	cohort	of	diverse	
patients	 provides	 evidence	 that	 in	 daily	 clinical	 practice,	 OBV/
PTV/r	±	DSV	±	RBV	 regimens	 are	 effective	 treatment	 options	 for	
patients	with	chronic	HCV	GT1	or	GT4	 infection,	 including	 those	
with	diverse	comorbidity	and	comedication	profiles.	As	with	other	
real-	world	studies,	safety	outcomes	may	be	limited	by	underreport-
ing	of	AEs.	The	high	degree	of	concordance	observed	between	our	
real-	world	data,	and	the	results	from	pivotal	clinical	trials	suggests	
that	the	reported	efficacy	of	OBV/PTV/r	±	DSV	±	RBV	regimens	in	
clinical	trials	translates	to	routine	clinical	practice.
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